APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2

J Immunol. 2006 Jun 1;176(11):6736-51. doi: 10.4049/jimmunol.176.11.6736.

Abstract

Of relevance to both protective and pathogenic responses to Ag is the recent finding that soluble molecules of the innate immune system, i.e., IL-4, B cell-activation factor of the TNF family (BAFF), and C3, exhibit significant synergy in promoting the clonal expansion of human B2 cells following low-level BCR ligation. Although IL-4, BAFF, and C3dg each contribute to early cell cycle entry and progression to S phase, only BAFF promotes later sustained viability of progeny needed for continued cycling. The present study sought to further clarify the mechanisms for BAFF's multiple functions. By comparing BAFF and a proliferation-inducing ligand (APRIL) efficacy at different stages in the response (only BAFF binds BR3; both bind transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B cell maturation Ag, the early role was attributed to BR3, while the later role was attributed to TACI/B cell maturation Ag. Importantly, BAFF- and APRIL-promoted viability of cycling lymphoblasts was associated with sustained expression of cyclooxygenase 2 (COX-2), the rate-limiting enzyme for PGE2 synthesis, within replicating cells. Supernatants of cultures with BAFF and APRIL contained elevated PGE2. Although COX-2 inhibitors diminished daughter cell viability, exogenous PGE2 (1-1000 nM) increased the viability and recovery of lymphoblasts. Increased yield of viable progeny was associated with elevated Mcl-1, suggesting that a BAFF/APRIL --> TACI --> COX-2 --> PGE2--> Mcl-1 pathway reduces activation-related, mitochondrial apoptosis in replicating human B2 cell clones.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • B-Cell Activating Factor
  • B-Cell Maturation Antigen
  • B-Lymphocyte Subsets / cytology*
  • B-Lymphocyte Subsets / drug effects
  • B-Lymphocyte Subsets / enzymology*
  • B-Lymphocyte Subsets / immunology
  • Cell Cycle / immunology
  • Cell Division / drug effects
  • Cell Division / immunology*
  • Cell Survival / drug effects
  • Cell Survival / immunology
  • Cells, Cultured
  • Child
  • Child, Preschool
  • Clone Cells
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 / physiology*
  • Cyclooxygenase Inhibitors / pharmacology
  • Humans
  • Immune Sera / pharmacology
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / immunology
  • Membrane Proteins / physiology*
  • Receptors, Antigen, B-Cell / physiology
  • Receptors, Tumor Necrosis Factor / immunology
  • Signal Transduction / immunology
  • Time Factors
  • Transmembrane Activator and CAML Interactor Protein
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • B-Cell Activating Factor
  • B-Cell Maturation Antigen
  • Cyclooxygenase Inhibitors
  • Immune Sera
  • Membrane Proteins
  • Receptors, Antigen, B-Cell
  • Receptors, Tumor Necrosis Factor
  • TNFRSF13B protein, human
  • TNFRSF17 protein, human
  • TNFSF13 protein, human
  • TNFSF13B protein, human
  • Transmembrane Activator and CAML Interactor Protein
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Tumor Necrosis Factor-alpha
  • Cyclooxygenase 2